These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 30511242)

  • 1. Genomic profile of breast sarcomas: a comparison with malignant phyllodes tumours.
    Lim SZ; Ng CCY; Rajasegaran V; Guan P; Selvarajan S; Thike AA; Nasir NDBM; Koh VCY; Tan BKT; Ong KW; Teh BT; Tan PH
    Breast Cancer Res Treat; 2019 Apr; 174(2):365-373. PubMed ID: 30511242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.
    Cani AK; Hovelson DH; McDaniel AS; Sadis S; Haller MJ; Yadati V; Amin AM; Bratley J; Bandla S; Williams PD; Rhodes K; Liu CJ; Quist MJ; Rhodes DR; Grasso CS; Kleer CG; Tomlins SA
    Mol Cancer Res; 2015 Apr; 13(4):613-9. PubMed ID: 25593300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MED12 is frequently mutated in breast phyllodes tumours: a study of 112 cases.
    Ng CC; Tan J; Ong CK; Lim WK; Rajasegaran V; Nasir ND; Lim JC; Thike AA; Salahuddin SA; Iqbal J; Busmanis I; Chong AP; Teh BT; Tan PH
    J Clin Pathol; 2015 Sep; 68(9):685-91. PubMed ID: 26018969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic landscapes of breast fibroepithelial tumors.
    Tan J; Ong CK; Lim WK; Ng CC; Thike AA; Ng LM; Rajasegaran V; Myint SS; Nagarajan S; Thangaraju S; Dey S; Nasir ND; Wijaya GC; Lim JQ; Huang D; Li Z; Wong BH; Chan JY; McPherson JR; Cutcutache I; Poore G; Tay ST; Tan WJ; Putti TC; Ahmad BS; Iau P; Chan CW; Tang AP; Yong WS; Madhukumar P; Ho GH; Tan VK; Wong CY; Hartman M; Ong KW; Tan BK; Rozen SG; Tan P; Tan PH; Teh BT
    Nat Genet; 2015 Nov; 47(11):1341-5. PubMed ID: 26437033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive genomic profiling of malignant phyllodes tumors of the breast.
    Nozad S; Sheehan CE; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon S; Schrock AB; Hirshfield KM; Ali N; Ganesan S; Ali SM; Miller VA; Stephens PJ; Ross JS; Chung JH
    Breast Cancer Res Treat; 2017 Apr; 162(3):597-602. PubMed ID: 28210881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast.
    Piscuoglio S; Murray M; Fusco N; Marchiò C; Loo FL; Martelotto LG; Schultheis AM; Akram M; Weigelt B; Brogi E; Reis-Filho JS
    Histopathology; 2015 Nov; 67(5):719-29. PubMed ID: 25855048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations.
    Otsuji K; Sasaki T; Tanabe M; Seto Y
    Br J Cancer; 2021 Jan; 124(2):466-473. PubMed ID: 33046803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent MED12 mutations in phyllodes tumours of the breast.
    Yoshida M; Sekine S; Ogawa R; Yoshida H; Maeshima A; Kanai Y; Kinoshita T; Ochiai A
    Br J Cancer; 2015 May; 112(10):1703-8. PubMed ID: 25839987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MED12 protein expression in breast fibroepithelial lesions: correlation with mutation status and oestrogen receptor expression.
    Tan WJ; Chan JY; Thike AA; Lim JC; Md Nasir ND; Tan JS; Koh VC; Lim WK; Tan J; Ng CC; Rajasegaran V; Nagarajan S; Bay BH; Teh BT; Tan PH
    J Clin Pathol; 2016 Oct; 69(10):858-65. PubMed ID: 27056456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast.
    Yoshida M; Ogawa R; Yoshida H; Maeshima A; Kanai Y; Kinoshita T; Hiraoka N; Sekine S
    Br J Cancer; 2015 Oct; 113(8):1244-8. PubMed ID: 26355235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MED12, TERT promoter and RBM15 mutations in primary and recurrent phyllodes tumours.
    Garcia-Dios DA; Levi D; Shah V; Gillett C; Simpson MA; Hanby A; Tomlinson I; Sawyer EJ
    Br J Cancer; 2018 Jan; 118(2):277-284. PubMed ID: 29315289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression.
    Piscuoglio S; Ng CK; Murray M; Burke KA; Edelweiss M; Geyer FC; Macedo GS; Inagaki A; Papanastasiou AD; Martelotto LG; Marchio C; Lim RS; Ioris RA; Nahar PK; Bruijn ID; Smyth L; Akram M; Ross D; Petrini JH; Norton L; Solit DB; Baselga J; Brogi E; Ladanyi M; Weigelt B; Reis-Filho JS
    J Pathol; 2016 Mar; 238(4):508-18. PubMed ID: 26832993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel genomic panel as an adjunctive diagnostic tool for the characterization and profiling of breast Fibroepithelial lesions.
    Sim Y; Ng GXP; Ng CCY; Rajasegaran V; Wong SF; Liu W; Guan P; Nagarajan S; Ng WY; Thike AA; Lim JCT; Nasir NDBM; Tan VKM; Madhukumar P; Yong WS; Wong CY; Tan BKT; Ong KW; Teh BT; Tan PH
    BMC Med Genomics; 2019 Oct; 12(1):142. PubMed ID: 31647027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MED12 exon 2 and TERT promoter mutations in primary and recurrent breast fibroepithelial lesions.
    Hu Y; Li G; Wang L; Zhang L; Guan J; Wang J
    Pathol Int; 2021 Dec; 71(12):814-822. PubMed ID: 34597441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MED12 exon 2 mutations in phyllodes tumors of the breast.
    Nagasawa S; Maeda I; Fukuda T; Wu W; Hayami R; Kojima Y; Tsugawa K; Ohta T
    Cancer Med; 2015 Jul; 4(7):1117-21. PubMed ID: 25865354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
    Simbolo M; Mafficini A; Sikora KO; Fassan M; Barbi S; Corbo V; Mastracci L; Rusev B; Grillo F; Vicentini C; Ferrara R; Pilotto S; Davini F; Pelosi G; Lawlor RT; Chilosi M; Tortora G; Bria E; Fontanini G; Volante M; Scarpa A
    J Pathol; 2017 Mar; 241(4):488-500. PubMed ID: 27873319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.
    Liu SY; Joseph NM; Ravindranathan A; Stohr BA; Greenland NY; Vohra P; Hosfield E; Yeh I; Talevich E; Onodera C; Van Ziffle JA; Grenert JP; Bastian BC; Chen YY; Krings G
    Mod Pathol; 2016 Sep; 29(9):1012-27. PubMed ID: 27255162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breast--implications for tumor biology and pathological diagnosis.
    Pfarr N; Kriegsmann M; Sinn P; Klauschen F; Endris V; Herpel E; Muckenhuber A; Jesinghaus M; Klosterhalfen B; Penzel R; Lennerz JK; Weichert W; Stenzinger A
    Genes Chromosomes Cancer; 2015 Jul; 54(7):444-52. PubMed ID: 25931199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel genetic aberrations in breast phyllodes tumours: comparison between prognostically distinct groups.
    Tan WJ; Lai JC; Thike AA; Lim JC; Tan SY; Koh VC; Lim TH; Bay BH; Tan MH; Tan PH
    Breast Cancer Res Treat; 2014 Jun; 145(3):635-45. PubMed ID: 24831776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent
    Pareja F; Da Cruz Paula A; Murray MP; Hoang T; Gularte-Mérida R; Brown D; da Silva EM; Sebastiao APM; Giri DD; Weigelt B; Reis-Filho JS; Brogi E
    J Clin Pathol; 2019 Mar; 72(3):258-262. PubMed ID: 30467240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.